Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
05/17/2023 Limited Information Icon NTRR Neutra Corp. From Pink Current To Pink Limited Common Stock
Limited Information Icon
Pink Limited Information
Delinquent SEC Reporting IconDelinquent SEC Reporting
Transfer Agent Verified IconTransfer Agent Verified
Tier Changes are posted on OTCmarkets.com at around 1:30 AM Monday to Friday mornings and to see them you can go to the OTC page under Market Activity then Corporate Actions then Symbol Changes dropdown then scroll down to Tier Changes .
https://www.otcmarkets.com/market-activity/corporate-actions
I was ask a ?
I own share if company stop reporting that is pink now long does the sec or otc let it go until not would be cone gray
What a relief. That sounds great for building stockholder value.
thank you for your insight....
If you believe being downgraded to gray is good for stock price....more power to you.
Do you Or any one know how look you can go with out reporting because they would put you in the gray market
Syd owes the investors an explanation:
Companies that fail to file within the allowed grace period are subject to a variety of costly penalties, including deregistration by the SEC, delisting by stock exchanges, the inability to raise capital through issuance of public securities, and potential debt covenant violations.
This is not a positive outcome. The NT provided 15 days and there has been no update. This is very concerning and certainly not positive for shareholders - very disappointing.
They said it will be filed by the end of May it’s with the auditor.
It appears the 10K filing deadline was missed????? Syd what is going on?
This is starting to get exciting again
Let’s see if market reacts to this!
News anytime I say Monday pre market or at open. I believe NTRR might have nailed this LOI to Mercury Clinical Research. All MY OPINIONS
They singed an NDA so he can’t give any information if they wanted to until it’s approved by Mercury CEO. Unfortunately this hold up is making NTRR look bad.
Come on Mr. Jim get this show on the road. :)
How about post the article rather than the link
Same here brother! If everything works out, our investment should definitely pay off. :)
Yeah. Hopefully something comes of it. I was more excited about the hemp farm etc that never came to fruition. One thing is for sure anything legit in medical research or trials is a no brainer to make big money. I'm still patiently waiting with a boatload of shares to cash in when the time is right.
We are. Just waiting on that acquisition news. Maybe Sydney needs to add some AI into the mix, lol.
nada 3s about to dump
What's going on with the volume here? I thought we were current.
I agree it will run. It always does. :)
Staying current is a plus for this security and it will eventually run in my view
OTC micros mostly red today but not NTRR and we are holding gains we made Tuesday
Joke here to. Damn 5 out of 5 In red! Maybe I should stop gambling in the otc lol
Well today was rather uneventful with 4.6 million shares traded and finishing flat for the day
Love to see this! Great news! :)
Next up, we should hear of the acquisition results before the end of April!
Go $NTRR!!!
Made money here in past, but somebody really doesn't want this to go up!??
"Mr. Gorbachev, tear down this wall!" :)
Dilution over for now…no more notes
Agreed let’s see a upward movement now!
JUST SMACKED THE 4 ASK!!!!! COME ON FOLKS HELP ME TAKE DOWN THESE 4’s!!!!!!! $NTRR
Neutra’s Strategic Move to Put the Organization in Position to Achieve Its Plans for Growth
Neutra Corp.
Tue, March 28, 2023 at 8:28 AM EDT·5 min read
In this article:
NTRR
-33.33%
Watchlist
Watchlist
Neutra Corp.
Neutra Corp.
KATY, TX, March 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neutra Corporation (OTC PINK:NTRR), an emerging health and wellness research and development company, last month announced the execution of a letter of intent to acquire Mercury Clinical Research, a privately-owned site management organization (SMO) comprised of a network of physicians conducting clinical trials for top-tier pharmaceutical companies. In preparation for the potential acquisition, the Company has taken the next steps to achieve a successful negotiation.
Neutra Corporation has retired the last of its debt from 2015. Shortly after the company announced that Power Up had completed their Series G Convertible Preferred Shares, the company relied on Power Up to provide funding for the next filing. As of the beginning of the 1st quarter 2023, Power Up has concluded their additional Series G Convertible Shares. The Company has not received any additional funding from Power Up since that time. Achieving the following has given Neutra the best position to move forward with the acquisition:
o Retired the last of its Debt; and
o Completion of additional Power Up Series G Convertible
"Putting Neutra in the best possible position to achieving this acquisition is one of my top priorities,” said Sydney Jim, Neutra Chief Executive Officer. “Not only will this acquisition increase the value to our shareholders, Neutra believes that having Mercury integrate with our team will allow us to achieve our overall goal in health, wellness, and life sciences."
Mercury, under its current management, has grown over twenty percent year over year in the last six years, with a 2022 gross revenue of between $3 and $7 million with industry-commensurate gross margins and positive EBITDA. Mercury will become a wholly owned subsidiary of the Company and is expected to place executives in senior management positions. Accordingly, there can be no assurance that a definitive agreement will be entered into or that the proposed transaction will be consummated.
"This potential acquisition is a strategic move that will position us to put our best foot forward in a growing research sector,” said Oscar Zedrick Buhay, Mercury Clinical Research Chief Executive Officer. “I hope that we can come to an agreement soon and really start pushing towards our mutual goals in advancing medicine.”
SMOs are rapidly becoming a bigger part of the pharmaceutical business as pharma companies have found them to be an increasingly valuable resource. SMOs were a $5.6 billion market in 2021. This could grow by 6.1% per year through 2030 thanks to increased research and development investments by pharmaceutical firms. SMOs offer clinical trial services to pharmaceutical companies and medical device companies. Collaborating with SMOs helps pharmaceutical companies get FDA approvals for medication, treatments, and/or devices.
Medications like SARS-CoV-2 vaccines and treatments, flu vaccines, testing devices, Alzheimer's treatments, etc., have been through trials aided by an SMO like the one Neutra intends to acquire, in order to become FDA approved before release to the public. In addition, SMOs also work with hospitals and private practices to provide alternative treatments available to help advance medicine.
About Neutra Corp.
Neutra Corp. (OTC: NTRR) is an early-stage research and development health and wellness company bringing modern healthy living solutions to a multi-billion-dollar market. Cutting-edge technologies within the nutraceuticals, food and drug, and life sciences are creating a new kind of world culture – one where consumers are demanding access to products that promote health and stave off potential health dangers.
Neutra is concentrating on developing into a vertically integrated company able to cultivate, manufacture and distribute hemp-based cannabidiol (CBD) products and hemp-based alternative cannabinoids. Hemp-based CBD consumer products generated sales of up to $390 million in 2018 with projections pointing to a $3 billion market by 2022, according to the Hemp Business Journal.
Neutra’s new broadened scope, which includes the commercialization of newer, more effective products, aims to capitalize on this worldwide boom. Our company is seeking new and exciting opportunities that can accelerate Neutra’s mission to promote a health and wellness through products and other ventures to a wider demographic. Our work reflects a renewed dedication to supporting a better body, environment, and life for people around the globe.
About Mercury
Mercury Clinical Research, Inc. (MCR) is an experienced site management organization comprised of a network of physicians conducting clinical trials in and around the greater Houston Area. MCR manages all aspects of the research program from marketing, regulatory, and safety reporting to coordination, patient scheduling, and query resolution. MCR has specific Budgeting, Regulatory, Data Management, Business Development, and Recruitment departments to ensure equal focus is given to every program need. For more information, visit the Company’s website at https://www.mercurycr.us.com.
NOTICE REGARDING FORWARD-LOOKING STATEMENTS
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words 'believes,' 'expects,' 'anticipate' or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.
Sydney Jim
281-728-7900
sjim@neutrainc.com
The Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2023, would subject hemp extract products to the regulatory framework for dietary supplements; while the CBD Product Safety and Standardization Act of 2023, would establish regulations for CBD as a food and beverage additive.
If this acquisition comes through, that will easily be eliminated within a year imo.
Check out Mercury Clinical Research company if you haven't already.
"We incurred a net loss of $632,926 for the year ended January 31, 2022 as compared to $538,892 for the comparable period of 2021. The increase in the net loss was primarily the result of higher general and administrative expense as discussed above."
https://www.sec.gov/ix?doc=/Archives/edgar/data/1512886/000116169722000224/form_10-k.htm
Sell me some 2's :)
It’s a start for Texas!
Texas Policy passed
Legislation which would reduce penalties for possession of cannabis flower and concentrates has passed out of committee!
HB 218, authored by Rep. Joe Moody of El Paso, advanced unanimously by the Criminal Jurisprudence Committee. It now heads to the Calendars Committee to be scheduled for consideration by the full Texas House of Representatives.
Ask your Representative to vote YES on HB 218!
Bill Highlights:
Possessing up to one ounce of cannabis or cannabis concentrates would be reduced to a Class C misdemeanor, with no jail time and a fine of no more than $500. Under existing law, possession of even the smallest amount of cannabis is a Class B misdemeanor, which can carry up to 180 days in jail and/or a fine of up to $2,000. Possession of any amount of cannabis concentrates is a felony, which carries a minimum jail term of between 180 days and two years.
Possession of up to two ounces would not result in an arrest if that was the only violation of the law. Currently anyone found in possession of any amount of cannabis is arrested and taken to jail in most jurisdictions.
Sets up an expungement process for possession of up to two ounces with a fee of $30 if certain conditions are met. This allows anyone with a low-level marijuana possession conviction to remove it from their criminal record.
Still here but in the background. Where I normally stay, out of sight and out of mind.
Barely! Looks like no interest in this the last month or so.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |